Federation Des Caisses Desjardins Du Quebec Monopar Therapeutics Transaction History

Federation Des Caisses Desjardins Du Quebec

  • $18.9 Billion
  • Q3 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$0.31 - $1.35 $24 - $108
80 New
80 $54,000

About Monopar Therapeutics

MNPR Quotes by TradingView
  • Ticker MNPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 12,725,800
  • Market Cap $316M
  • Description
  • Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...
More about MNPR
Track This Portfolio

Track Federation Des Caisses Desjardins Du Quebec Portfolio

Follow Federation Des Caisses Desjardins Du Quebec and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Federation Des Caisses Desjardins Du Quebec, based on Form 13F filings with the SEC.

News

Stay updated on Federation Des Caisses Desjardins Du Quebec with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email